PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Nafarelin acetate - Transgender Health - Children & Young People

PAD Profile : Nafarelin acetate - Transgender Health - Children & Young People

Keywords :
gonadorelin analogues, GnRH analogues, LHRH analogues, hormone therapy, gender reassignment, sex change, gender incongruence, transsexuals, transgender, hormone manipulation, puberty supression, masculinisation, feminisation, gender dysphoria
Brand Names Include :
Synarel

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Nasal spray
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Education material (for healthcare personnel)

Committee Recommendations

Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for puberty supressing hormones in children and young people under the following circumstances:
i.    ONLY for current NHS and private patients at least until next reviewed by the service lead clinician.  Always ensure that appropriate shared care protocols are in place before continuing prescribing.  Private patients should be advised of the new NHS policy and recommendation made to return to the private provider for consideration of stopping.
ii.    DO NOT initiate in any new patients

Associated BNF Codes

06. Endocrine System
06.07.02. Drugs affecting gonadotrophins
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More